… To our knowledge, there are no reports that would include renal biopsy findings in helping …
or not to stop eculizumab. Following the rationales to continue or discontinue eculizumab (the …

… eculizumab treatment in 10 patients who stopped treatment … The rationale for discontinuation
was to reduce the risk of … on patients’ quality of life, prevent the development of immune-…

… This advance facilitated the development of novel, rational treatment options targeting …
children with a clinical diagnosis of aHUS, we propose eculizumab as first-line treatment, to avoid …

… Is it safe to stop eculizumab therapy? Is there a need for prophylactic use of eculizumab in
… the relapse rate after discontinuation of eculizumab in children, which ranges between 16 …

… The rationale for PE and PI is to replace absent or mutated … Eculizumab therapy in children
with severe hematopoietic … Adult-onset eculizumab-resistant hemolytic uremic syndrome …

… microangiopathy (TMA) and severe end-organ damage. Based … diagnosis that was not aHUS,
1 had unspecified reasons. aHUS, … of eculizumab in a prospective clinical trial in children. …

… of their TMA and improvement of the putative trigger of their TMA, as outlined in the supplemental
Methods. Of the 15 patients who stopped eculizumab with … Clinician rationale for not …

… The studies were not controlled for 2 reasons: because there was … Eculizumab for atypical
hemolytic uremic syndrome … The authors make the point that in children—or anyone weighing …

… 17], 31% of patients who stopped eculizumab treatment experienced TMA … The purpose of
this study is to assess TMA manifestations in patients with … Atypical hemolytic uremic syndrome …

… in older children, revealing the benefits of eculizumab after … or placebo may be difficult
because of ethical reasons. … be recommended to stop TMA progression and to avoid irreversible …